Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression

8 Dec 2017

Abstract excerpt

// Jai-Nien Tung 1, * , Po-Lin Lin 2, * , Yao-Chen Wang 3 , De-Wei Wu 2 , Chi-Yi Chen 4 and Huei Lee 2 1 Department of Neurosurgery, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan 2 Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan 3 Department of Internal Medicine, Chung Shan Medical University and Hospital, Taichung, Taiwan 4 Department of Surgery, Chung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hippo pathway signaling and YAP/TAZ
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29435131
DOI: 10.18632/oncotarget.23161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expressionPMID 29435131Read ↗

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.Semantic proximity Read ↗

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.Semantic proximity Read ↗

The new idea of cancer immunotherapy: the expression of PD-L1 may reveal the immunological mechanism of resistance of EGFR-TKIsSemantic proximity Read ↗

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancerSemantic proximity Read ↗

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistanceSemantic proximity Read ↗

Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.Semantic proximity Read ↗

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.Semantic proximity Read ↗

PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.Semantic proximity Read ↗

Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression.Semantic proximity Read ↗

Study on Targeted Drugs for Non-Small Cell NSCLC with PD-1PD-L1 Signaling Pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.